Tier 2 — strong

Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Review

Kothe B, Klein S, Petrosky SN
Cureus 2023 15(7):e42550

Bibliography

PubMed
PMID 37637627
PubMed Central
PMC10460156
DOI
10.7759/cureus.42550

Study snapshot

DesignScoping review
Model15 included primary publications on Urolithin A and age-related pathology
Sample15 publications
InterventionLiterature synthesis of Urolithin A supplementation/intervention studies
DurationNot applicable
EndpointsNeurodegenerative disease models; Musculoskeletal outcomes; Cardiovascular and metabolic models; Mitochondrial dysfunction and mitophagy

What the study showed, in plain terms

This 2023 scoping review maps the breadth of Urolithin A research across aging-related disease areas. It is useful for deciding which future content clusters deserve dedicated evidence audits, but it should not be read as proof that Urolithin A prevents age-related disease in humans.

Key findings

Fifteen publications met the review's criteria.

The literature spans neurodegenerative, musculoskeletal, cardiovascular and other age-related disease models.

Mitophagy and mitochondrial quality control are recurring mechanistic themes.

What this study can and cannot tell us

Scoping reviews map literature rather than estimate pooled efficacy.

Much of the included evidence is preclinical.

The review cannot establish disease prevention in humans.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology